Can you provide the last earnings date for EUPRAXIA PHARMACEUTICALS INC?
EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) last reported earnings on 11/4/2025.
TSX:EPRX • CA29842P1053
Past quarterly earnings results for EUPRAXIA PHARMACEUTICALS INC (EPRX.CA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.26 | -0.22 | -18.58% | -12.93% | - | - | ||
| Q2 2025 | -0.36 | -0.25 | -41.57% | -54.51% | - | - | ||
| Q1 2025 | -0.30 | -0.24 | -23.87% | -6.36% | - | - | ||
| Q4 2024 | -0.28 | -0.16 | -80.04% | 26.32% | - | - | ||
| Q3 2024 | -0.23 | -0.27 | 12.99% | 7.20% | - | - | ||
| Q2 2024 | -0.23 | -0.24 | 2.06% | 35.28% | - | - | ||
| Q1 2024 | -0.28 | -0.35 | 18.21% | -23.04% | - | - | ||
| Q4 2023 | -0.38 | -0.24 | -55.23% | 7.32% | - | - | ||
| Q3 2023 | -0.25 | -0.33 | 23.41% | - | - | - | ||
| Q2 2023 | -0.36 | -0.37 | 1.96% | - | - | - | ||
| Q1 2023 | -0.23 | -0.37 | 37.36% | - | - | - | ||
| Q4 2022 | -0.41 | -0.44 | 6.52% | -51.85% | - | - | ||
| Q3 2022 | - | - | - | - | ||||
| Q2 2022 | - | - | - | - | ||||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | -0.27 | -0.43 | 36.97% | - | - | - | ||
| Q3 2021 | -0.22 | - | - | - | - | |||
| Q2 2021 | -0.38 | -0.56 | 31.64% | - | - | - | ||
| Q1 2021 | -0.86 | -0.14 | -524.55% | - | - | - | ||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) last reported earnings on 11/4/2025.
EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) has beaten EPS estimates in 0 out of 4 releases.